Torcetrapib (CP-529,414, Pfizer) was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease...

a combination of torcetrapib and atorvastatin, an increase in cardiovascular events and mortality. A compound related to torcetrapib, Dalcetrapib (investigative...

in deaths (torcetrapib), or having no meaningful clinical improvement despite HDL increases (dalcetrapib, evacetrapib). Failed: Torcetrapib: failed in...

Pfizer's CETPi drug (torcetrapib) failed in the final stages of clinical development. Pfizer terminated the development program for torcetrapib and reportedly...

increasing HDL by any means is not necessarily helpful. For example, the drug torcetrapib is the most effective agent currently known for raising HDL (by up to...

replacing Henry McKinnell. On December 3, 2006, Pfizer ceased development of torcetrapib, a drug that increases production of HDL, which reduces LDL thought to...

previous acute coronary events. Other CETP inhibitors:[citation needed] Torcetrapib was developed by Pfizer until December 2006 but caused unacceptable increases...

Cholesteryl ester transfer protein (CETP) inhibitors include the agents torcetrapib, anacetrapib and obicetrapib. They block transfer of cholesterol from...

modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone...

cardiovascular risk score for early detection of the harmful effects of Torcetrapib. In 2016 they also developed a test to diagnose latent tuberculosis,...